ParagonDx gets approval for genetic blood thinner test

05/5/2008 | News & Observer (Raleigh, N.C.), The

The FDA has granted ParagonDx clearance to market a genetic test that can detect the sensitivity of heart-attack and stroke patients to the blood thinner warfarin. The product, which is expected to be available in a few months, can cut the risk of excessive bleeding among patients taking warfarin.

View Full Article in:

News & Observer (Raleigh, N.C.), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL